A recent paper in the journal "Blood" from the Mayo myeloma group draws attention to the fact that some patients with MGUS—Monoclonal Gammopathy of Undetermined Significance—can have renal damage from the M-component, and even complete renal failure in some instances. They propose a new name for this subtype of patient: MGRS – Monoclonal Gammopathy of Renal Significance. This is certainly helpful and draws attention to a whole range of clinical problems that can emerge from the effects of the M-component in serum and/or urine produced in MGUS patients. Possible neuropathy is widely recognized, but there can also be a range of autoimmune disorders affecting muscle (myositis), skin (dermatitis), blood vessel (arteritis) and even blood components resulting in, for example, acquired hemophilia or Von Willebrand’s bleeding disorders. So we need to be more aware of these clinical issues which are significant and not undetermined, according to Dr. Brian G.M. Durie, Chairman and Co-founder of the IMF. It may be we will end up with several new acronyms. If the acronym MGRS sticks, this may just be the beginning of a trend.
Click here to view the abstract of the "Blood" article.